Tevogen Bio

Specialty immunotherapy biotech developing off-the-shelf precision T cell therapeutics.

[Tevogen @Tevogen]

📰 https://t.co/Juuq8qFYJ0

Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements
🔹Both previously disclosed Nasdaq compliance matters are now closed

$TVGN @Nasdaq #Compliance

[Tevogen @Tevogen]

📰 https://t.co/sPVNWWgudP

Tevogen is a healthcare enterprise focused on improving the affordability and accessibility of life-saving medicines. The Company brings together three complementary efforts: @TevogenBio, its biotechnology initiative; @TevogenAI, its artificial intelligence and technology initiative; and @TevogenHS its healthcare services, its emerging healthcare services initiative.

Together, these efforts are designed to create a more integrated healthcare model in which science, technology, and operational efficiency work together to reduce the cost of medication and expand patient access.

“We are not simply building a biotechnology company. We are building a healthcare enterprise,” said @DrRyanSaadi, MD, MPH, Founder and Chief Executive Officer of Tevogen.

#TVGN

[Tevogen @Tevogen]

Tevogen Bio Announces 2026 Annual Meeting of Stockholders

📰 https://t.co/qhYwEYCy6x

The Annual Meeting will be held virtually. Stockholders of record as of July 23, 2026 will be entitled to receive notice of and vote at the Annual Meeting or any adjournment thereof.

$TVGN

[Tevogen Bio @TevogenBio]

Tevogen Bio Announces 2026 Annual Meeting of Stockholders

📰 https://t.co/DcwjiJJbya

The Annual Meeting will be held virtually. Stockholders of record as of July 23, 2026 will be entitled to receive notice of and vote at the Annual Meeting or any adjournment thereof.

$TVGN

[Tevogen @Tevogen]

🇺🇸 Happy Fourth of July from Tevogen. Today, we celebrate independence, opportunity, and the shared pursuit of a healthier future for all.

$TVGN #USA250 #IndependenceDay #July4th

[Tevogen @Tevogen]

A little #TBT to a day we will never forget.
We are proud of how far we have come, and even more energized by where we are headed.
$TVGN @Nasdaq @TevogenAI @Tevogen

[Ryan Saadi, Founder, TEVOGEN @DrRyanSaadi]

The most powerful pharmacy in the world isn’t on a street corner. It’s already inside our veins. @TevogenBio - #Tcell
🌐 https://t.co/9FOwy8XEKJ $TVGN

[Tevogen @Tevogen]

📰 https://t.co/0Rj0z1Tq5A

“Tevogen’s evaluation of potential MSO and CRO acquisitions reflects a disciplined approach to building revenue-generating capabilities that may support long-term financial self-sufficiency,” said Kirti Desai, Chief Financial Officer at Tevogen. “With approximately $100 million in potential combined annual revenue under evaluation, we believe these opportunities could represent an important step toward strengthening the Company’s financial foundation while remaining aligned with our mission to make healthcare more affordable and accessible.”

$TVGN #HealthcareEnterprise #StrategicAcquisitions #Revenue @DrRyanSaadi

[Tevogen @Tevogen]

At JPM43 Mittul Mehta, @Head_TevogenAI and @drhew
Chief Medical Officer & VP of Healthcare at
@Microsoft discussed AI in Biopharma: Next Frontier of Medical Innovation

$TVGN $MSFT @DrRyanSaadi #Healthcare #ArtificialIntelligence #AI #Innovation #ICYMI

[Tevogen Bio @TevogenBio]

RT @TevogenBio: Dr. Neal Flomenberg, Chief Scientific Officer, and Lori Grosso, Clinical Lead, discussed @TevogenBio's goal of making cytot…

[Tevogen Bio @TevogenBio]

RT @TevogenBio: 📰 https://t.co/A0DpFyP70F

“Capital discipline and preserving the integrity of our capital structure are core priorities fo…

[Tevogen @Tevogen]

📰 https://t.co/GGtieRNxdZ

“We anticipate this opportunity together with previously announced CRO evaluation and other strategic acquisition initiatives, if consummated, could potentially pave Tevogen’s path to realizing approximately $100 million in combined annual revenue,” said Tevogen founding CEO @DrRyanSaadi

$TVGN #StrategicAcquisitions #RevenueGeneration #HealthcareEnterprise

[Tevogen @Tevogen]

📰 https://t.co/BHcnJowd5K

🔹Loss from operations declined 51%, from $53.6 million in 2024 to $26.1 million in 2025.

🔹Q1 2026 showed continued improvement, with loss from operations decreasing to $5.4 million, a 48% improvement year-over-year.

🔹The Company is evaluating potential revenue-generating acquisitions that may support positive cash flow and business diversification.

🔹The Company continues to prioritize disciplined capital allocation and avoiding unnecessary dilution.

More in the link.
Thank you for your continued trust and support.

$TVGN #ShareholderValue #CapitalDiscipline

[Tevogen @Tevogen]

📰 https://t.co/MJvMGLLyoU

“Having The Patel Family, LLP continue to support Tevogen reflects a shared belief in both our mission and our long-term vision for building a more accessible and sustainable healthcare model,” said Tevogen founding CEO @DrRyanSaadi. “We believe this financing along with an existing ATM offering and loan agreement, provides the company with access to adequate capital to reach revenue milestones.

$TVGN #PIPE #RevenueGrowth #HealthcareInnovation

[Tevogen @Tevogen]

📰 https://t.co/tMwk9ax3lO

“Advancing PredicTcell toward completion marks an important milestone in our AI strategy,” said @Head_TevogenAI Mittul Mehta, “As we begin exploring commercial pathways, our focus remains on maintaining scientific rigor while building scalable tools that can extend the impact of our platform beyond internal use.”

$TVGN #PredicTcell #ArtificialIntelligence #MachineLearning #DrugDiscovery #Immunotherapy

[Tevogen @Tevogen]

🔗 https://t.co/CvvZCoRGzs

As part of our ongoing work on PredicTcell™, we’ve been leveraging scalable data infrastructure to process and analyze hundreds of millions of peptide sequences across diverse disease areas.

This recent feature by @databricks highlights elements of that journey, how modern data architecture can support complex biological modeling and help move from static datasets toward adaptive, continuously learning systems.

Thank you, Databricks, for supporting @TevogenAI’s journey toward what we consider the “holy grail”: 𝘵𝘩𝘦 𝘢𝘣𝘪𝘭𝘪𝘵𝘺 𝘵𝘰 𝘱𝘳𝘦𝘥𝘪𝘤𝘵 𝘵𝘩𝘦 𝘱𝘳𝘰𝘵𝘦𝘰𝘮𝘦 𝘧𝘰𝘳 𝘢𝘯𝘺 𝘨𝘪𝘷𝘦𝘯 𝘤𝘰𝘮𝘣𝘪𝘯𝘢𝘵𝘪𝘰𝘯 𝘰𝘧 𝘱𝘳𝘰𝘵𝘦𝘪𝘯 𝘢𝘯𝘥 𝘏𝘓𝘈 𝘵𝘺𝘱𝘦.

$TVGN #ArtificialIntelligence #MachineLearning #Bioinformatics #DataEngineering #AIinHealthcare

[Tevogen @Tevogen]

📰 https://t.co/FwYDYfvrHc

With compliance restored, Tevogen continues to advance its evolution into a diversified, fully integrated healthcare enterprise, combining immunotherapy, artificial intelligence, and disciplined capital allocation to drive long-term value.

The Company’s strategic direction includes evaluating targeted acquisition opportunities that complement its core platforms. These initiatives are part of a broader effort to transition toward a cash-flow-positive operating model while maintaining a strong commitment to affordability and efficiency.

$TVGN #Nasdaq

[Tevogen @Tevogen]

📰 https://t.co/6zUI9q74SM

@DrRyanSaadi, Founder and CEO of Tevogen stated, "Long COVID is a clinical emergency affecting hundreds of millions of people globally. Our proof-of-concept data demonstrated that none of the patients treated with TVGN 489 for acute infection developed Long COVID. Our expanded HLA coverage now reaching 65% of the U.S. population, and potential digital health acquisitions move us toward building the infrastructure needed to launch our next clinical phase with precision and scale."

$TVGN #LongCOVID #TCellTherapy #PublicHealth #LongCOVIDAwareness #LongCOVIDAwarenessMonth

[Tevogen Bio @TevogenBio]

RT @TevogenBio: 📰 https://t.co/1Q83ya3Zkr

“The potential acquisition of a CRO could introduce revenue-generating service capabilities whil…

[Tevogen Bio @TevogenBio]

@TevogenBio @TevogenAI @DrRyanSaadi The potential transaction is being explored to augment Tevogen’s existing capabilities and would result in Tevogen becoming a revenue-generating healthcare enterprise.

$TVGN #Sciometrix #Clinicus #HealthcareTechnology #Revenue #Strategy

[Tevogen Bio @TevogenBio]

📰 https://t.co/NbkjzEnqZU

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

$TVGN #Sciometrix #Clinicus #HealthcareTechnology #Revenue #Strategy @TevogenBio @TevogenAI